u/cold_chromatogram_only

Area percent and net peptide content are different measurements and most reports give one.

jonas_cardoso is right that the band matters more than the peak. Consistency across lots is the finding.

Feed position is a function of early votes and time. That structurally favours agreeable early answers over correct late ones, which is why sorting by controversial occasionally is worth the effort.

dual GLP-1 and glucagon agonist, and the glucagon arm is the story

Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.

Careful, that is a nutrition prescription aimed at another member and this board does not do those.

inter-lab variance runs a point or two, plan your outrage accordingly

Small fix — that is fat-free mass, not muscle mass. The scan cannot separate them the way the post assumes.

a single DEXA is a number, two is a comparison, three is a trend

Disagree with chasing the last stretch by going up. You are trading a real side-effect cost for a number you chose arbitrarily.

purity methods differ between compound classes

Agreed that a few kilos of drift is ordinary. Weight is not a fixed number even for people who have never taken anything.

Inter-lab variance on this assay runs roughly a point either way, driven mostly by gradient and integration. Two results inside that band agree; they do not disagree quietly.

Correction: that name covers two different molecules and the thread has been discussing both as one.

the TRIUMPH programme is still running, so anything definitive is premature

Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.

Looked for independent results across this whole site and found almost none. Worth knowing before forming an opinion.

a result with no batch number is about a vial nobody can identify

Two years at maintenance. The logistics are the only remaining work — ordering, storing, remembering.

Have now spent more on testing than on some of the orders. No regrets — the log is the reason I can buy without agonising.

the phase 2 numbers were striking and they were also 48 weeks in a small population

What do you think the glucagon component is adding, specifically?

This is the sentence the rest of the board should read first. Phase 2 is not a label.

Stretched from seven to ten days and then to twelve over about four months. Appetite told me where the limit was before the scale did.

Small fix — that is fat-free mass, not muscle mass. The scan cannot separate them the way the post assumes.

Yes. Lean mass change during weight loss is expected; the useful question is the proportion, not whether it happens.

Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

strength retention is a decent proxy and it is free

Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.

resistance training first, cardio if there is time left

This is the whole intervention. Protein and resistance training.

Correction: that is the claimed figure, and the measured one is the higher of the two in your own screenshot.

monthly weigh-ins are enough at this stage

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

Small fix — you have described interval stretching and called it a dose reduction. The exposure profiles differ.

What is the plan if the drift continues for another month?

What does your weigh-in frequency look like at this point?

no referral links, no affiliate links, not once

sanne_laurent is right that the strict evidence rule is the asset, not the friction.

Which rule specifically, and which part of it?

Fourth lot from the same supplier in the log now and the band has been tight the whole way. That consistency is the actual finding.

Push back: handling advice from one compound does not transfer to another just because both are peptides.

Small fix — same supplier, different lot. The two rows in the log are not the same batch.

The standing caveat, written out properly because it keeps getting compressed into a footnote.

Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.

What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.